|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.100 CAD | 0.00% |
|
0.00% | +20.90% |
| Jan. 02 | InnoCan Pharma to List on NYSE American Next Week | MT |
| Jan. 02 | Innocan Pharma Corp Brief: Anticipates Listing on NYSE American Stock Exchange with Concurrent Offering | MT |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
Assets | |||||||
Cash And Equivalents | 2.34M | 11.05M | 4.95M | 3.88M | 5.01M | ||
Total Cash And Short Term Investments | 2.34M | 11.05M | 4.95M | 3.88M | 5.01M | ||
Accounts Receivable, Total | 2K | - | 62K | 249K | 250K | ||
Other Receivables | 1.13M | 169K | 181K | 445K | 286K | ||
Total Receivables | 1.13M | 169K | 243K | 694K | 536K | ||
Inventory | 430K | 510K | 1.13M | 1.75M | 3.32M | ||
Prepaid Expenses | 309K | 715K | 453K | 340K | 67K | ||
Other Current Assets, Total | 72K | 79K | 104K | 138K | 219K | ||
Total Current Assets | 4.28M | 12.52M | 6.88M | 6.8M | 9.15M | ||
Net Property Plant And Equipment | 56K | 54K | 98K | 136K | 113K | ||
Total Assets | 4.33M | 12.58M | 6.98M | 6.94M | 9.26M | ||
Liabilities | |||||||
Accounts Payable, Total | 527K | 53K | 95K | 112K | 185K | ||
Accrued Expenses, Total | 384K | 432K | 318K | 463K | 478K | ||
Current Portion of Leases | 37K | 1K | 14K | 22K | 10K | ||
Other Current Liabilities | 6.99M | 3.08M | 304K | 1.95M | 1.56M | ||
Total Current Liabilities | 7.94M | 3.56M | 731K | 2.54M | 2.24M | ||
Long-Term Leases | 1K | - | 20K | 11K | - | ||
Total Liabilities | 7.94M | 3.56M | 751K | 2.55M | 2.24M | ||
Common Stock, Total | - | - | - | - | - | ||
Additional Paid In Capital | 10.96M | 33.66M | 34.77M | 37.18M | 40.08M | ||
Retained Earnings | -14.56M | -24.61M | -28.37M | -33.07M | -34.91M | ||
Total Common Equity | -3.61M | 9.06M | 6.39M | 4.1M | 5.17M | ||
Minority Interest | - | -44K | -169K | 283K | 1.86M | ||
Total Equity | -3.61M | 9.01M | 6.22M | 4.39M | 7.02M | ||
Total Liabilities And Equity | 4.33M | 12.58M | 6.98M | 6.94M | 9.26M | ||
Supplemental Items | |||||||
ECS Total Shares Outstanding on Filing Date | 3.31M | 3.82M | 3.87M | 4.32M | 4.48M | ||
ECS Total Common Shares Outstanding | 2.9M | 3.82M | 3.84M | 4.12M | 4.46M | ||
Book Value / Share | -1.24 | 2.37 | 1.66 | 1 | 1.16 | ||
Tangible Book Value | -3.61M | 9.06M | 6.39M | 4.1M | 5.17M | ||
Tangible Book Value Per Share | -1.24 | 2.37 | 1.66 | 1 | 1.16 | ||
Total Debt | 38K | 1K | 34K | 33K | 10K | ||
Net Debt | -2.3M | -11.05M | -4.91M | -3.85M | -5M | ||
Minority Interest, Total (Incl. Fin. Div) | - | -44K | -169K | 283K | 1.86M | ||
Account Code - Inventory Valuation | - | 5 | 5 | 5 | 5 | ||
Inventories - Raw Materials, Total | 203K | 188K | 224K | 214K | 184K | ||
Inventories - Finished Goods, Total | 227K | 322K | 907K | 1.53M | 3.27M | ||
Full Time Employees | - | - | - | - | - | ||
Part Time Employees | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
















